The AHA Aug. 17 provided comments to the Centers for Medicare & Medicaid Services on its proposed rule to codify in regulation the Medicare Drug Price Negotiation Program. The AHA recommended CMS require drug manufacturers to make the maximum fair price available through a point-of-sale mechanism and eliminate any option permitting manufacturers to meet their obligations through retrospective rebates or post-sale reconciliations. The AHA expressed concerns that permitting retrospective MFP effectuation could set a foundation for broader manufacturer efforts to move the federal 340B program away from upfront discounts and toward a rebate-based model. The AHA also urged CMS to ensure that any future guidance or rulemaking regarding MFP availability maintains clear national standards and avoids permitting manufacturer-specific approaches that could create inconsistency across products and markets.
Healthcare · Policy
AHA Offers Recommendations on CMS Medicare Drug Price Negotiation Rule
The American Hospital Association has submitted comments to CMS regarding the proposed rule to codify the Medicare Drug Price Negotiation Program, advocating for point-of-sale maximum fair prices and expressing concerns about potential impacts on the 340B program.
1 sources
Pipeline ingest
3 reads
Positive / Neutral / Negative
1 countries
Related coverage
PAN's pipeline reviewed approximately 1 open sources for this article. No human editor reviewed this article before publication.
